Blood-brain barrier, cytotoxic chemotherapies and glioblastomaReport as inadecuate

Blood-brain barrier, cytotoxic chemotherapies and glioblastoma - Download this document for free, or read online. Document in PDF available to download.

* Corresponding author 1 ICM - Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute 2 Hôpital Saint-Louis 3 Service de neurologie 2 CHU Pitié-Salpêtrière 4 Service de Neurochirurgie CHU Pitié-Salpêtrière

Abstract : Introduction: Glioblastomas GBM are the most common and aggressive primary malignant brain tumors in adults. The blood brain barrier BBB is a major limitation reducing efficacy of anti-cancer drugs in the treatment of GBM patients.Areas covered: Virtually all GBM recur after the first-line treatment, at least partly, due to invasive tumor cells protected from chemotherapeutic agents by the intact BBB in the brain adjacent to tumor. The passage through the BBB, taken by antitumor drugs, is poorly and heterogeneously documented in the literature. In this review, we have focused our attention on: i the BBB, ii the passage of chemotherapeutic agents across the BBB and iii the strategies investigated to overcome this barrier.Expert commentary: A better preclinical knowledge of the crossing of the BBB by antitumor drugs will allow optimizing their clinical development, alone or combined with BBB bypassing strategies, towards an increased success rate of clinical trials.

Keywords : Glioblastoma blood-brain barrier cytotoxic chemotherapy pharmacokinetics delivery

Author: Antonin Dréan - Lauriane Goldwirt - Maïté Verreault - Michael Canney - Charlotte Schmitt - Jeremy Guehennec - Jean-Yves Delatt



Related documents